Publication date: May 26, 2026
“Because our study was limited to postmenopausal women 60 years and older with type 2 diabetes, its generalizability to men and younger populations is unknown,” the study authors caution. “We found that metformin initiation increased exceptional longevity compared with sulfonylurea initiation among women with type 2 diabetes. “There are sex differences in type 2 diabetes, with women having a higher cardiometabolic risk factor burden at the time of diagnosis than men. Further, women with diabetes have higher risk of mortality than men. “A key goal of geroscience is to identify novel therapeutic and preventive interventions that slow biological aging. “The research has been published in the Journal of Gerontology: Medical Sciences. An earlier version of this article was published in June 2025. The overall sample size wasn’t particularly large, either.
| Concepts | Keywords |
|---|---|
| Diabetes | Aging |
| Germany | Diabetes |
| Healthier | Drug |
| Scientists | Follow |
| Long | |
| Longevity | |
| Metformin | |
| Older | |
| Published | |
| Risk | |
| Study | |
| Sulfonylurea | |
| Women | |
| Write |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Metformin |
| disease | MESH | type 2 diabetes |
| drug | DRUGBANK | Tropicamide |
| disease | MESH | long COVID |